Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4504538 | 0.81 | ALDH1A1 (0.47) | KDM4EADORA2AADORA1CYP2C9MEN1 | |
| SCHEMBL10810550 | 0.79 | NPSR1 (0.53) | KDM4EADORA2AADORA1ADORA2BNPSR1 | |
| SCHEMBL14318699 | 0.76 | KDM4E (0.41) | KDM4EADORA2AADORA1NPSR1PTGS1 | |
| SCHEMBL2133864 | 0.74 | LHCGR (0.60) | KDM4EMEN1KMT2A | |
| SCHEMBL4515441 | 0.74 | ADORA3 (0.53) | KDM4ENPSR1LMNA | |
| SCHEMBL3061862 | 0.73 | MAP4K4 (0.48) | KDM4EADORA2AADORA1ADORA2BDPP4 | |
| SCHEMBL5592931 | 0.73 | KDM4E (0.52) | KDM4EADORA1IDO1LMNACYP1A2 | |
| SCHEMBL2132337 | 0.71 | LHCGR (0.60) | — | |
| SCHEMBL11185290 | 0.68 | KDM4E (0.43) | KDM4EADORA2AADORA1DPP4IDO1 | |
| SCHEMBL1101918 | 0.68 | KDM4E (1.00) | KDM4EADORA1NPSR1LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7494989-B2 | Pyridine compounds useful as N-type calcium channel antagonists | AJINOMOTO CO., INC. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20080070903-A1 | NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES | AJINOMOTO CO., INC (JP) | 2008-03-20 | — | — | US | disclosed |
| US-7288544-B2 | Pyrimidine compounds useful as N-type calcium channel antagonists | AJINOMOTO CO., INC. (JP) | 2007-10-30 | — | — | US | disclosed |
| US-20040009991-A1 | Pyrimidine derivatives and new pyridine derivatives | AJINOMOTO CO., INC. (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1318147-A1 | NOVEL PYRIMIDINE DERIVATIVE AND NOVEL PYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2003-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070903-A1 | NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES | P2RY10, CACNA1B, CACNA1E | KDM4E 3546/4885ADORA2A 152/4885ADORA1 92/4885 |
| US-20040009991-A1 | Pyrimidine derivatives and new pyridine derivatives | CACNA1I, CACNA1B, CACNA1E | KDM4E 3327/4885ADORA2A 141/4885ADORA1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.